Quantbot Technologies LP Purchases Shares of 47,700 Supernus Pharmaceuticals, Inc. $SUPN

Quantbot Technologies LP acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 47,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,219,000. Quantbot Technologies LP owned about 0.08% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in shares of Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after buying an additional 193,479 shares in the last quarter. Mystic Asset Management Inc. purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $1,181,000. Rice Hall James & Associates LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $22,800,000. Allworth Financial LP acquired a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $2,357,000. Finally, Westover Capital Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $1,587,000.

Supernus Pharmaceuticals Stock Down 1.6%

SUPN stock opened at $45.11 on Tuesday. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -23.49, a PEG ratio of 0.85 and a beta of 0.56. The business has a fifty day simple moving average of $46.77 and a 200-day simple moving average of $48.80. Supernus Pharmaceuticals, Inc. has a 52 week low of $42.45 and a 52 week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the previous year, the business posted $0.40 EPS. Supernus Pharmaceuticals’s revenue was up 32.4% compared to the same quarter last year. As a group, analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SUPN shares. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.